From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Fevertree's 2019 results prove to be a tonic...but what about the Covid-19 mixer?...

By Chris Bailey | Wednesday 22 April 2020

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Three months ago I asked the question, Has Fevertree (FEVR) completely lost its fizz? – concluding that 'it might have a nice product but it is not yet a good enough GARP stock to buy without a belief in a speculative bid approach'. That looked a smart call with the share falling from fourteen quid and change back in January to a low point of barely nine quid a month ago. However it - along with a number of stocks and sectors across the market - has bounced back strong and after a romp today has pierced the fifteen quid level at the time of writing, albeit this is still half of the 52 week high and even further behind the all-time high...

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Video: Poking Bears And Black Swans



Is Stuart Ashman lying again?



So farewell then

Time left: 07:29:00